RAMM Pharma Corp. provides the latest litigation information from Investing.com

Not for distribution in the US or through US Newswire Services

TORONTO, Dec. 11, 2024 (GLOBE NEWSWIRE) — RAMM Pharma Corp. (including its wholly owned subsidiaries, Company or “RAMM”) (CSE: RAMM)provides an update on its dispute with Sergio Martinez and Naturale Science Inc. (plaintiffs), as previously announced in its press release dated May 21, 2024.

The judge dismissed the plaintiffs’ claim in the amount of CAD 3,139,931.30 and awarded Martinez CAD 14,971.80 in unpaid costs. The judge also dismissed RAMM’s counterclaim in the amount of CAD 14,220,000.

The reasons for the judgment, published on December 9, 2024, can be accessed on the website of the Ontario Superior Court of Justice.

About RAMM Pharma Corp.

RAMM Pharma is active in the field of cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other hemp-based products with a unique and diverse international manufacturing and sales platform. The company operates with an established pharmaceutical and medicinal products company in Uruguay that has developed several medically registered and approved herbal cannabinoid pharmaceutical products that are approved for sale and/or compassionate use in several Latin American countries. RAMM also has a number of new products, including registered hemp-based nutrition and specialty veterinary products, in various stages of approval and development, which are manufactured to a state-of-the-art, certified Good Manufacturing Practice formulation. facility in Montevideo, Uruguay.

In Europe, RAMM’s vertically integrated operations are based in Ragusa, Italy and ElblA…g, Poland (60 kilometers east of Gdańsk), and include large extraction and processing plants (in the final stages of commissioning in the case of Canapar Corp. ) . RAMM Pharma includes wholly owned subsidiaries Canapar Corp., HemPoland Sp. Z o. o., Medic Plast SA, Iurelan SA, Gladiser SA and RAMM Pharma Holdings Corp.

Additional information about the Company is available at www.vearerammpharma.com.

For further information please contact:

JosA¨ Roldan
Interim CFO
+598 99 057 301
jroldan@rammpharma.com

Caution regarding forward-looking information

This release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements“) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as of the date of this release. Any statement that includes a discussion with respect to predictions, expectations, beliefs, plans, projections, goals, assumptions, future events or performance (often, but not always, using phrases such as expectations or does not expect, is expected, anticipates or does not anticipate, plans, budgets, plans, predicts, estimates, believes or intends or variations of such words and phrases or stating that certain actions, events or results may or could, would, could or will be considered to occur or be achieved) are not statements of historical fact and may be statements relating to future strategy and objectives and future expansion plans.

These forward-looking statements are based on the Company’s management’s reasonable assumptions and estimates at the time such statements are made. Actual future results may differ materially because forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause the Company’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied. such forward-looking statements. Such factors include, but are not limited to: the resolution of the litigation being pursued and defended by Ramm; financial risk related to litigation; the amount accumulated in the Company’s financial statements in connection with the litigation; the Company’s future growth potential; fluctuations in general macroeconomic conditions; fluctuations in the securities market; expectations regarding the size of the Uruguayan, Latin American, European and international medical and recreational cannabis markets and changing consumer habits; the Company’s ability to successfully achieve its business goals; expansion plans; political and social uncertainties; impossibility of obtaining adequate insurance to cover risks and dangers; and the presence of laws and regulations that may impose restrictions on the cultivation, production, distribution and sale of cannabis and cannabis-related products in Uruguay or internationally; and employee relations. Although the forward-looking statements contained in this press release are based on what the Company’s management believes or at the time believed to be reasonable assumptions, the Company cannot assure stockholders that actual results will be consistent with such statements. forward-looking, because there may be other factors that cause the results to not be as expected expected, estimated or intended. Readers should not place undue reliance on the statements and information contained in this press release. The Company undertakes no obligation to update any forward-looking statements regarding beliefs, opinions, projections or other factors, should they change, except as required by law.

No stock exchange, securities commission or other regulatory body has approved or disapproved of the information contained in this document.

Source: RAMM Pharma Corp.